CO7061040A2 - Anticuerpos contra la metaloproteinasa de la matriz 9 - Google Patents

Anticuerpos contra la metaloproteinasa de la matriz 9

Info

Publication number
CO7061040A2
CO7061040A2 CO14190943A CO14190943A CO7061040A2 CO 7061040 A2 CO7061040 A2 CO 7061040A2 CO 14190943 A CO14190943 A CO 14190943A CO 14190943 A CO14190943 A CO 14190943A CO 7061040 A2 CO7061040 A2 CO 7061040A2
Authority
CO
Colombia
Prior art keywords
metalloproteinase
antibodies against
eacute
against matrix
immunoglobulin
Prior art date
Application number
CO14190943A
Other languages
English (en)
Inventor
Victoria Smith
Scott Mccauley
Original Assignee
Gilead Biologics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Biologics Inc filed Critical Gilead Biologics Inc
Publication of CO7061040A2 publication Critical patent/CO7061040A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24035—Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G01N2333/96491—Metalloendopeptidases (3.4.24) with definite EC number
    • G01N2333/96494—Matrix metalloproteases, e. g. 3.4.24.7

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Composiciones que comprenden proteínas que pueden unirse a la proteína metaloproteinasa de la matriz 9 (MMP9, que también se conoce como la gelatinasa B) y que están compuestas por una cadena pesada de una inmunoglobulina (Ig), o un fragmento funcional de ésta, y una cadena liviana de una inmunoglobulina, o un fragmento funcional de ésta, que por ejemplo, pueden tomar la forma de anticuerpos o de fragmentos de éstos que pueden unirse a los antígenos. Métodos para usar dichas composiciones.
CO14190943A 2012-02-29 2014-08-29 Anticuerpos contra la metaloproteinasa de la matriz 9 CO7061040A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2012/027160 WO2013130078A1 (en) 2012-02-29 2012-02-29 Antibodies to matrix metalloproteinase 9

Publications (1)

Publication Number Publication Date
CO7061040A2 true CO7061040A2 (es) 2014-09-19

Family

ID=45816000

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14190943A CO7061040A2 (es) 2012-02-29 2014-08-29 Anticuerpos contra la metaloproteinasa de la matriz 9

Country Status (23)

Country Link
US (4) US9550836B2 (es)
EP (1) EP2820048B1 (es)
JP (1) JP6067756B2 (es)
KR (1) KR20140130724A (es)
CN (1) CN104395345A (es)
AP (1) AP2014007907A0 (es)
AU (4) AU2012318302C1 (es)
BR (1) BR112014021477A2 (es)
CA (1) CA2865530C (es)
CL (1) CL2014002282A1 (es)
CO (1) CO7061040A2 (es)
CR (1) CR20140443A (es)
EA (1) EA201491575A1 (es)
EC (1) ECSP14020504A (es)
ES (1) ES2731441T3 (es)
HK (2) HK1205153A1 (es)
IN (1) IN2014DN08011A (es)
MD (1) MD20140107A2 (es)
MX (1) MX2014010449A (es)
PH (1) PH12014501931A1 (es)
SG (1) SG11201405305PA (es)
WO (1) WO2013130078A1 (es)
ZA (1) ZA201406319B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2608809T3 (pl) 2010-08-27 2019-10-31 Gilead Biologics Inc Przeciwciała dla metaloproteinazy 9 macierzy
US9550836B2 (en) 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
CN104271156B (zh) * 2012-02-29 2017-06-16 吉利德生物制剂公司 抗基质金属蛋白酶9的抗体
CA2940869A1 (en) * 2014-02-27 2015-09-03 Gilead Sciences, Inc. Antibodies to matrix metalloproteinase 9 and methods of use thereof
EP2985295A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
EP2985296A1 (en) 2014-08-13 2016-02-17 Calypso Biotech SA Antibodies specific for MMP9
CN105037553B (zh) * 2015-08-20 2018-04-17 内蒙古蒙元生物基因科技有限公司 一种能够检测癌症的免疫球蛋白
CA3019003A1 (en) 2016-04-08 2017-10-12 Gilead Sciences, Inc. Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
US10326830B1 (en) * 2016-09-02 2019-06-18 Amazon Technologies, Inc. Multipath tunneling to a service offered at several datacenters
WO2018109222A1 (en) 2016-12-16 2018-06-21 Universite de Bordeaux Mmp9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder
WO2018170488A1 (en) 2017-03-17 2018-09-20 Gilead Sciences, Inc. Method of purifying an antibody
US11926655B2 (en) 2017-07-18 2024-03-12 Daiichi Sankyo Company, Limited Active MMP9-binding peptide
CN110885375B (zh) * 2019-12-20 2021-07-02 南京融捷康生物科技有限公司 特异性针对mmp-9蛋白锌离子结合结构域的单域抗体及产品与应用
CN111785321B (zh) * 2020-06-12 2022-04-05 浙江工业大学 一种基于深度卷积神经网络的dna绑定残基预测方法
CN117327186B (zh) * 2023-07-12 2024-03-12 北京达成生物科技有限公司 结合mmp3蛋白的双特异性抗体及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
ES2327812T3 (es) * 1999-07-13 2009-11-04 University Of Southern California Nuevos metodos y composiciones para inhibir la angiogenesis utilizando bases antagonistas de mmp-9 y/o integrinas beta-1.
CN1459505A (zh) * 2002-05-21 2003-12-03 赵平 中国汉族人基质金属蛋白酶－9基因重构、表达、纯化及其医学应用
ES2614274T3 (es) * 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
KR101434682B1 (ko) * 2005-12-02 2014-08-27 제넨테크, 인크. 결합 폴리펩티드 및 이들의 용도
PE20090765A1 (es) * 2007-06-08 2009-07-10 Irm Llc Metodos y composiciones para inducir la apoptosis en celulas cancerosas
WO2009111508A2 (en) * 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 9 and metalloproteinase 2 binding proteins
JP2011517662A (ja) * 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
US20110262396A1 (en) * 2008-10-22 2011-10-27 Dyax Corp. Combination treatments comprising protease binding proteins for inflammatory disorders
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
EA201270701A1 (ru) * 2010-01-27 2013-01-30 Йеда Рисеч Энд Девелопмент Ко. Лтд. Ингибирующие металлопротеины антитела
PL2608809T3 (pl) 2010-08-27 2019-10-31 Gilead Biologics Inc Przeciwciała dla metaloproteinazy 9 macierzy
US9550836B2 (en) 2012-02-29 2017-01-24 Gilead Biologics, Inc. Method of detecting human matrix metalloproteinase 9 using antibodies
CN104271156B (zh) 2012-02-29 2017-06-16 吉利德生物制剂公司 抗基质金属蛋白酶9的抗体

Also Published As

Publication number Publication date
HK1205153A1 (en) 2015-12-11
JP2015514394A (ja) 2015-05-21
AU2012318302A1 (en) 2013-09-19
AP2014007907A0 (en) 2014-08-31
US11634505B2 (en) 2023-04-25
CA2865530A1 (en) 2013-09-06
US10800857B2 (en) 2020-10-13
MD20140107A2 (ro) 2015-03-31
MX2014010449A (es) 2015-02-10
US9550836B2 (en) 2017-01-24
ES2731441T3 (es) 2019-11-15
AU2017216508A1 (en) 2017-08-31
IN2014DN08011A (es) 2015-05-01
SG11201405305PA (en) 2014-09-26
CA2865530C (en) 2019-02-19
AU2015242967B2 (en) 2017-08-24
JP6067756B2 (ja) 2017-01-25
AU2017216508B2 (en) 2019-03-07
CN104395345A (zh) 2015-03-04
BR112014021477A2 (pt) 2018-06-12
US20170183421A1 (en) 2017-06-29
AU2012318302B2 (en) 2016-08-18
AU2012318302C1 (en) 2017-06-15
CR20140443A (es) 2014-11-17
NZ629888A (en) 2017-02-24
AU2015242967A1 (en) 2015-11-05
AU2017261626A1 (en) 2017-12-07
CL2014002282A1 (es) 2015-02-20
US20210054101A1 (en) 2021-02-25
PH12014501931A1 (en) 2014-11-24
ECSP14020504A (es) 2015-09-30
KR20140130724A (ko) 2014-11-11
HK1208036A1 (en) 2016-02-19
EA201491575A1 (ru) 2015-01-30
US20190127486A1 (en) 2019-05-02
ZA201406319B (en) 2016-02-24
EP2820048B1 (en) 2019-04-17
US20150140580A1 (en) 2015-05-21
WO2013130078A1 (en) 2013-09-06
EP2820048A1 (en) 2015-01-07

Similar Documents

Publication Publication Date Title
CO7061039A2 (es) Anticuerpos dirigidos contra metaloproteinasas de matriz 9
CO7061040A2 (es) Anticuerpos contra la metaloproteinasa de la matriz 9
CR20130132A (es) Anticuerpos contra metalproteasa-9 de matriz
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
CO7151488A2 (es) Anticuerpos de reacción cruzada anti-jagged1/jagged 2, anticuerpos anti-jagged activables y métodos de uso de los mismos
CR20150575A (es) Anticuerpos humanos pac1
CO2021002954A2 (es) Anticuerpos anti-αvβ8 y composiciones y usos de los mismos
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
BR112022009723A2 (pt) Anticorpos específicos para cd47, pd-l1, e usos dos mesmos
CO2018012513A2 (es) Anticuerpos
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
AR093620A1 (es) Anticuerpos bmp-6
EA201691414A1 (ru) Антитела к матриксной металлопротеиназе 9 и способы их применения
AR118080A2 (es) Proteínas de unión a antígeno dirigidas contra el receptor